Poor
Not Aligned
Patient Risk:
High
Summary
The AI output contains many claims about acetaminophen liver/kidney risks and NSAID comparisons that are not supported by the provided CODRIX™ FDA label excerpts (which focus on codeine-containing product risks such as respiratory depression, habit formation/abuse, ultra-rapid metabolizers, alcohol/CNS depressants, and pregnancy/nursing). Several claims are therefore unsupported relative to the supplied label text.
Category Scores
Accurate Statements
Seek urgent medical care if there are signs of liver trouble such as jaundice, dark urine, severe abdominal pain, confusion, or bleeding.
Partially supported only insofar as CODRIX™ label excerpt includes acetaminophen overdosage leading to serious hepatic injury (Section 10: 'dose-dependent, potentially fatal hepatic necrosis') and codeine overdosage includes severe toxicity features (Section 10: 'loss of consciousness' and opioid triad). The specific symptom set listed is not explicitly present in the provided excerpts.
Unsupported Statements
Acetaminophen is mainly broken down by the liver.
Not stated in the provided CODRIX™ label excerpts.
Long-term use of acetaminophen, especially at higher doses, can increase the risk of liver injury.
Provided label excerpt mentions acetaminophen overdosage causing 'dose-dependent, potentially fatal hepatic necrosis' (Section 10) but does not support long-term use/high-dose risk wording in the supplied text.
The risk of liver injury from acetaminophen is higher when daily dosing is above recommended limits.
Not supported by the provided excerpt; only overdose toxicity is described (Section 10) without 'daily dosing above recommended limits' phrasing.
The risk of liver injury from acetaminophen is higher when alcohol intake is significant.
Not supported in the provided CODRIX™ excerpts (only alcohol/CNS-depressant additive CNS depression is described in Sections 7 and 5).
Acetaminophen-related liver injury can range from mild enzyme elevations to severe hepatitis and liver failure.
Not stated in the provided excerpts.
Long-term use of acetaminophen can cause kidney problems in some people.
Not stated in the provided CODRIX™ excerpts.
Higher cumulative acetaminophen use has been associated with chronic kidney disease in certain populations.
Not stated in the provided excerpts.
Most adult guidance limits total daily acetaminophen to 4,000 mg per day from all sources.
No numeric acetaminophen daily maximum (e.g., 4,000 mg/day) appears in the provided CODRIX™ excerpts.
Many clinicians recommend staying lower than 4,000 mg/day (for example, 3,000 mg/day) for a safety margin, especially for people who use it regularly.
Not stated in the provided label excerpts.
Acetaminophen in combination cold/flu, pain, and sleep products can lead to exceeding the daily maximum if total doses from all products are not counted.
Not stated in the provided label excerpts.
Alcohol use, especially regular or heavy drinking, increases vulnerability of the liver to acetaminophen injury.
Not stated in the provided excerpts.
Taking doses above the recommended daily maximum, including accidentally by combining multiple products, increases the risk of acetaminophen side effects.
Not stated in the provided excerpts (the excerpt addresses acetaminophen overdosage causing hepatic necrosis, but not 'recommended daily maximum' or combination-product guidance).
The liver risk of acetaminophen is dose- and time-related.
Not stated in the provided excerpts.
Pre-existing liver disease or conditions that affect liver metabolism increase the risk of acetaminophen side effects.
The provided excerpt includes caution in 'severe impairment of renal or hepatic function' (Section 5) but does not specifically tie increased acetaminophen side effect risk to 'pre-existing liver disease' or 'conditions that affect liver metabolism' in the manner claimed.
Symptoms of liver injury from acetaminophen can include nausea, vomiting, loss of appetite, right upper belly pain, unusual fatigue, dark urine, pale stools, and yellowing of the skin/eyes (jaundice).
These specific liver-injury symptom details are not stated in the provided excerpts.
Severe liver injury from acetaminophen can lead to confusion, bleeding, or swelling.
Not stated in the provided excerpts for acetaminophen liver injury; while codeine overdosage includes loss of consciousness (Section 10), the specific linkage to acetaminophen severe liver injury symptoms is not supported.
Early symptoms of kidney-related problems from acetaminophen can include fatigue, swelling in the legs/ankles, or changes in urination.
Not stated in the provided excerpts.
Kidney damage from acetaminophen may be detected first by blood/urine tests rather than obvious symptoms.
Not stated in the provided excerpts.
Compared with NSAIDs such as ibuprofen or naproxen, acetaminophen is much less associated with stomach ulcers and GI bleeding.
Not addressed in the provided excerpts.
Acetaminophen does not primarily block prostaglandins in the stomach in the same way as NSAIDs.
Not addressed in the provided excerpts.
Long-term GI effects are not the main concern with acetaminophen; liver and kidney risks are the key issues.
Not supported in the provided excerpts (and kidney/GI framing is not supported).
For chronic pain, the main long-term risks of acetaminophen are liver injury (especially with alcohol or high total daily dose) and possible kidney risk.
Not supported in the provided excerpts; 'kidney risk' and alcohol-enhanced liver injury are not supported by the provided label text.
For chronic pain, NSAID main concerns include stomach/intestinal bleeding, ulcers, and increased cardiovascular risk in some patients.
Not addressed in the provided excerpts (and concerns are for NSAIDs, not CODRIX label content provided).
Clinicians often tailor choices between acetaminophen and NSAIDs based on comorbidities such as liver disease, kidney function, GI history, and heart risk.
Not stated in the provided excerpts.
One should check with a clinician before using acetaminophen regularly if they have liver disease or prior liver injury from medication.
The provided excerpt includes caution for severe hepatic impairment (Section 5), but does not provide this specific patient advice language for 'regular use' and 'prior liver injury from medication.'
One should check with a clinician before using acetaminophen regularly if they have ongoing heavy alcohol use.
While alcohol/CNS depressants avoidance is stated (Sections 5/7), the specific 'heavy alcohol use' instruction and linkage to 'regular acetaminophen' is not explicitly supported.
One should check with a clinician before using acetaminophen regularly if they have significant kidney disease.
The provided excerpt advises caution in 'severe impairment of renal or hepatic function' (Section 5) but does not provide this specific 'significant kidney disease' and 'check with a clinician before using acetaminophen regularly' directive.
One should check with a clinician before using acetaminophen regularly if they take other medicines that may contain acetaminophen.
Not stated in the provided excerpts.
One should check with a clinician before using acetaminophen regularly if they need daily pain relief long term, including to consider safer strategies and monitor labs.
Not stated in the provided excerpts.
If someone has used acetaminophen frequently for weeks to months, it is reasonable to add up total daily dose from all products containing acetaminophen.
Not stated in the provided excerpts.
If someone has used acetaminophen frequently for weeks to months, it is reasonable to talk to a clinician about whether to get liver and kidney tests.
Not stated in the provided excerpts.
If someone has used acetaminophen frequently for weeks to months, it is reasonable to review alternatives for chronic pain, including non-drug strategies, topical options, or other medication classes depending on the situation.
Not stated in the provided excerpts.
Contradictions
Important Omissions
Key CODRIX-specific safety points about codeine (e.g., respiratory depressant effects enhanced with head injury/intracranial lesions; habit-forming/abuse and not recommended for extended use; ultra-rapid metabolizers may experience overdose symptoms even at labeled dosing; avoid alcohol/CNS depressants; avoid driving/operating machinery; pregnancy and nursing risks).
Importance:
High
Accurate product-context: CODRIX is acetaminophen + codeine; the output focuses heavily on acetaminophen-only liver/kidney issues without reflecting codeine-related warnings present in the provided label excerpts.
Importance:
High
Safety Assessment
Potential Patient Risk:
High
The response includes many unsupported acetaminophen liver/kidney and dosing-limit claims and omits multiple prominent CODRIX-specific codeine warnings from the provided label excerpts (e.g., respiratory depression risk, ultra-rapid metabolizers, habit-forming/abuse, alcohol/CNS-depressant additive effects, and pregnancy/nursing fatal infant risk). This mismatch could misdirect attention away from label-critical risks.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Most claims are not supported by the provided CODRIX™ label excerpts, and the response underemphasizes multiple codeine-specific boxed-warning-equivalent/section 5 and section 7 safety elements present in the label text.
Suggested Improvement
Restrict claims to what is present in the provided CODRIX™ label excerpts (Sections 4/5/7/8/10) and avoid adding acetaminophen-only long-term dosing, numeric daily limits, NSAID comparisons, and kidney-risk assertions unless the label text explicitly supports them.